19/02/2020
Marie Skłodowska-Curie Actions

Call for 4 PhD fellowships within the Marie Skłodowska-Curie ITN project PAVax: A training network for the design of new synthetic carbohydrate-based vaccines to combat antibiotic resistant Pseudomonas aeruginosa and Staphylococcus aureus

This job offer has expired


  • ORGANISATION/COMPANY
    Leiden University
  • RESEARCH FIELD
    ChemistryBiochemistry
    ChemistryOrganic chemistry
  • RESEARCHER PROFILE
    First Stage Researcher (R1)
  • APPLICATION DEADLINE
    31/05/2020 23:00 - Europe/Brussels
  • LOCATION
    Netherlands › Leiden
    Italy › Siena
  • TYPE OF CONTRACT
    Temporary
  • JOB STATUS
    Full-time
  • HOURS PER WEEK
    40
  • OFFER STARTING DATE
    01/09/2020
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • MARIE CURIE GRANT AGREEMENT NUMBER
    861194

OFFER DESCRIPTION

Introduction

The PAVax project is a network that will train 4 Early-Stage Researchers (ESRs) on the conception of new synthetic vaccines to combat the antibiotic resistant bacteria Pseudomonas aeruginosa (PA) and Staphylococcus aureus (SA), for which there currently is no adequate vaccine available. The four selected ESRs will experience an intersectorial, international and interdisciplinary training encompassing 18 months at the academic partner Leiden University (NL) and 18 months at the industrial partner GlaxoSmithKline Vaccines (GSKVACSRL), based in Siena (IT). The close collaboration between the two partners will ensure training of the ESRs at the highest level and with the best synergy possible in the fields of (synthetic) carbohydrate chemistry, vaccine design, protein chemistry and conjugation, biophysical interaction studies, and immunology. In addition, all students will participate in a series of scientific, technical and complementary skills training events.

The students will be enrolled in the PhD school programme at Leiden University (NL) for a period of 4 years.

 

Research Projects

PAVax is an innovative, doctoral training network that aims at the education of a new generation of glycoscientists able to provide key findings for the design of new carbohydrate-based vaccines for the prevention of PA and SA infection.

Aim of PAVax is to explore and exploit the use of PA and SA-oligosaccharides to generate novel vaccines targeting these exposed polysaccharides. Next to the isolation of these polysaccharides from the bacteria, synthetic chemistry will be employed to deliver well-defined fragments of these polysaccharides. These will be used to map the interactions of the saccharides with antibodies to inform on the structure of the optimal epitope. Conjugation of the (synthetic) fragments to carrier proteins will lead to the generation of conjugate vaccines.

 

The four projects have been defined in:

  •  ESR1: Chemical and immunochemical characterization of Pel and Psl. The scope of this project is to gain information on composition and immunological properties of exopolysaccharides from PA. The polysaccharides will be isolated and characterized to produce conjugates that will be used to generate specific sera for investigating their recognition of biofilms from different PA strains and probing their functional activity. (Planned start date for ESR1: 1st September 2020)

 

  • ESR2: Chemical conjugation of PA and SA polysaccharide fragments to PA and SA proteins where, PA is P. aeruginosa and SA is S. aureus. The fellow will express a variety of PA and SA proteins to be tested as carrier for carbohydrates. Glycan conjugation strategies will be designed for selectively modify the protein and preserve their immunological properties. Chemistry will be developed to construct multicomponent vaccine candidates. The conjugates will be evaluated in vivo and generated sera screened through in vitro assays. (Planned start date for ESR2: 1st September 2020)

 

  • ESR3: Synthesis and epitope mapping of Staphylococcus aureus glycans. This project will focus on the development of (automated) synthesis techniques to generate well-defined fragments of S. aureus glycans. The generated library of structures will be used for antibody binding studies and the generation of model vaccine entities. (Planned start date for ESR3: 1st September 2020)

 

  • ESR4: Epitope mapping of Pseudomonas aeruginosa surface polysaccharides. This project will focus on the development of synthesis techniques to generate well-defined fragments of complex P. aeruginosa exopolysaccharides. The generated library of structures will be used for antibody binding studies and the generation of model vaccine entities. (Planned start date for ESR4: 1st September 2020)

 

Training Programme

The training programme comprises:

  • Research training activities, performed locally, leading to award of the PhD title.
  • Scientific/technical training courses and activities performed locally and at the project level to train the ESRs in scientific topics, advanced technology and methodologies necessary for the project implementation.
  • Transferable skills training to prepare the ESRs for an academic or industrial career will be provided through local and joint training courses.
  • Scientific events, such as 6 project meetings and 1 mid-term meeting, where the fellows will be required to present their achievements and progress to a senior audience.

 

More Information

Benefits

All 4 ESRs will be enrolled at the in the PhD school programme at “University of Leiden” for a period of 4 years. ESR1 and ESR2 will be contractually employed for 36 months by GlaxoSmithKline Vaccines Srl (Italy) while ESR3 and ESR4 will be contractually employed for 36 months by University of Leiden (Netherlands). Extension to the fourth PhD year is foreseen. After 18 months the students will switch the working location to the other Partner.

The ESRs will be covered under the social security scheme of the enrolling country. He or she will monthly receive a Living Allowance, a Mobility Allowance and a Family Allowance (if applicable) compliant with the applicable EC Marie Skłodowska-Curie Actions-ITN general conditions (see https://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-msca_en.pdf page 80).

The PhD positions are part of an Innovative Training Network (ITN) and the ESRs to be employed will benefit from a personal career development plan with targeted training measures and participation in a range of network activities with the other PAVax consortium partner.

Eligibility criteria

At the time of recruitment, applicants must fulfill the following rules:

 

Experience eligibility requirement:

  • Eligible applicants must have a Master/Engineering degree and must be in the first four years of their research careers (full-time equivalent research experience) and have not yet been awarded a doctoral degree.

Mobility eligibility requirement:

  • ESR1 and ESR2: applicants can be of any nationality but, at the time of recruitment, may not have resided or carried out their main activity in Italy for more than 12 months in the 3 years immediately prior to the recruitment date.
  • ESR3 and ESR4: applicants can be of any nationality but, at the time of recruitment, may not have resided or carried out their main activity in the Netherlands for more than 12 months in the 3 years immediately prior to the recruitment date.

Selection process

Application Procedure

Applications for the PhD positions ESR1 and ESR2 should be addressed to Dr. Roberto Adamo.

Applications for the PhD positions ESR3 and ESR4 should be addressed to Dr. Jeroen Codée.

All application should be sent at j.e.van.krimpen@lic.leidenuniv.nl with the subject “application PAVax”

 

The application must be accompanied with the following documents in PDF format:

  • a letter giving reason for his/her motivation for the position
  • an updated CV of at most 3 pages; the CV must be without gaps, in order to easily check the mobility and experience requirements. CVs that either do not clearly show the applicant’s past experience, or have gaps, will be considered ineligible.
  • two written recommendation letters (in English) e.g. from your Master thesis supervisor and/or lecturer and the referees contact details
  • the copy of the degree (usually the Master Degree)
  • transcripts of records (document indicating the ranking and marks within the last year at the Master Degree as well as the courses/modules that have been followed) from University/University College.
  • a copy of master’s thesis or any other publication (if available)

Planned start date for all ESRs: 1st September 2020

The deadline for application is 31st May 2020

 

Applications must be in English and will be evaluated against the following criteria:

- Educational record

- scientific quality of the applicant’s CV

- expected individual impact and benefit to the fellow and to the project

- previous experience in the subject of PAVax research programme.

 

The candidates will be evaluated on the basis of the received documents and the best 2-3 candidates for each position will be invited for a F2F / Skype interview that will take place in June/July 2020.

As an equal opportunity employer Leiden University is committed to increase the percentage of female scientists and therefore especially encourages them to apply.

Additional comments

ESR1 and ESR2 will be contractually employed for 36 months by GlaxoSmithKline Vaccines Srl (Italy) while ESR3 and ESR4 will be contractually employed for 36 months by University of Leiden (Netherlands). After 18 months the students will switch the working location to the other Partner.

All 4 ESRs will be enrolled at the in the PhD school programme at “University of Leiden” for a period of 4 years. The students will receive the fellowship within the Marie Skłodowska-Curie Actions Program for the first 36 months. Extension to the fourth PhD year is foreseen.

Web site for additional job details

Required Research Experiences

  • RESEARCH FIELD
    ChemistryOrganic chemistry
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4
  • RESEARCH FIELD
    ChemistryBiochemistry
  • YEARS OF RESEARCH EXPERIENCE
    1 - 4

Offer Requirements

  • REQUIRED EDUCATION LEVEL
    Chemistry: Master Degree or equivalent
  • REQUIRED LANGUAGES
    ENGLISH: Excellent

Skills/Qualifications

The candidates must have a Master/Engineering Degree in Chemistry (Organic Chemistry, Biochemistry, Medicinal Chemistry). A suitable background for the open position includes Synthetic Organic Chemistry. A background in Chemical Biology will be appreciated. In case of equal qualification, candidates with background in Synthetic Carbohydrate Chemistry will be preferred.

 

 

 

Specific Requirements

The candidate should have excellent communication skills in English (both in speaking and writing). A recognized international certificate in English (TOEFL, TOEIC, etc) would be a plus. He/She should be able to work both in a team and independently, should demonstrate initiative and should be proactive in the project.

Work location(s)
2 position(s) available at
Leiden University
Netherlands
Leiden
2333 CC
Einsteinweg 55
2 position(s) available at
GlaxoSmithKline Vaccines SRL
Italy
Siena
53100
Via Fiorentina 1

EURAXESS offer ID: 494969

Disclaimer:

The responsibility for the jobs published on this website, including the job description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.

 

Please contact support@euraxess.org if you wish to download all jobs in XML.